MCAC on age-related macular degeneration
This article was originally published in The Gray Sheet
Executive Summary
CMS' Medicare Coverage Advisory Committee will convene Nov. 29 in Baltimore to discuss age-related macular degeneration treatments. In 2004, the agency approved coverage for photodynamic therapy with QLT/Novartis' Visudyne (verteporfin) in patients who have occult and minimally classic lesions (1"The Gray Sheet" Feb. 2, 2004, p. 16). Alcon, Miravant Medical Technologies and Occulogix are also developing age-related macular degeneration products...